134 related articles for article (PubMed ID: 12729396)
1. Analyzing randomized dose finding studies with a primary and a secondary endpoint.
Hothorn LA; Wassmer G
J Biopharm Stat; 2003 May; 13(2):301-5. PubMed ID: 12729396
[TBL] [Abstract][Full Text] [Related]
2. [Introduction to randomized trials: the choice of endpoint].
Simon EG; Fouché CJ; Perrotin F
Gynecol Obstet Fertil; 2011 Oct; 39(10):595-6. PubMed ID: 21924939
[No Abstract] [Full Text] [Related]
3. How to deal with multiple treatment or dose groups in randomized clinical trials?
Hothorn LA
Fundam Clin Pharmacol; 2007 Apr; 21(2):137-54. PubMed ID: 17391286
[TBL] [Abstract][Full Text] [Related]
4. Two-stage designs for dose-finding trials with a biologic endpoint using stepwise tests.
Polley MY; Cheung YK
Biometrics; 2008 Mar; 64(1):232-41. PubMed ID: 17573866
[TBL] [Abstract][Full Text] [Related]
5. Test and power considerations for multiple endpoint analyses using sequentially rejective graphical procedures.
Bretz F; Maurer W; Hommel G
Stat Med; 2011 Jun; 30(13):1489-501. PubMed ID: 21290405
[TBL] [Abstract][Full Text] [Related]
6. Testing non-inferiority and superiority for two endpoints for several treatments with a control.
Lawrence J
Pharm Stat; 2011; 10(4):318-24. PubMed ID: 20949636
[TBL] [Abstract][Full Text] [Related]
7. A consistency-adjusted strategy for accommodating an underpowered primary endpoint.
Huque MF; Alosh M
J Biopharm Stat; 2012; 22(1):160-79. PubMed ID: 22204533
[TBL] [Abstract][Full Text] [Related]
8. Defining the optimal activated clotting times during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials.
Helft G; Beygui F; le Feuvre C; Metzger JP
Circulation; 2001 Nov; 104(22):E124. PubMed ID: 11723037
[No Abstract] [Full Text] [Related]
9. Design of vaccine equivalence/non-inferiority trials with correlated multiple binomial endpoints.
Kong L; Kohberger RC; Koch GG
J Biopharm Stat; 2006; 16(4):555-72. PubMed ID: 16892913
[TBL] [Abstract][Full Text] [Related]
10. Adaptive Dc-optimal designs for dose finding based on a continuous efficacy endpoint.
Padmanabhan SK; Dragalin V
Biom J; 2010 Dec; 52(6):836-52. PubMed ID: 20891026
[TBL] [Abstract][Full Text] [Related]
11. Joint hypothesis testing and gatekeeping procedures for studies with multiple endpoints.
Mascha EJ; Turan A
Anesth Analg; 2012 Jun; 114(6):1304-17. PubMed ID: 22556210
[TBL] [Abstract][Full Text] [Related]
12. Hierarchical testing of multiple endpoints in group-sequential trials.
Glimm E; Maurer W; Bretz F
Stat Med; 2010 Jan; 29(2):219-28. PubMed ID: 19827011
[TBL] [Abstract][Full Text] [Related]
13. Partition testing in dose-response studies with multiple endpoints.
Liu Y; Hsu J; Ruberg S
Pharm Stat; 2007; 6(3):181-92. PubMed ID: 17654696
[TBL] [Abstract][Full Text] [Related]
14. Identifying the maximum safe dose: a multiple testing approach.
Hothorn LA; Hauschke D
J Biopharm Stat; 2000 Feb; 10(1):15-30. PubMed ID: 10709798
[TBL] [Abstract][Full Text] [Related]
15. Addressing multiplicity issues of a composite endpoint and its components in clinical trials.
Huque MF; Alosh M; Bhore R
J Biopharm Stat; 2011 Jul; 21(4):610-34. PubMed ID: 21516560
[TBL] [Abstract][Full Text] [Related]
16. Multiple comparisons and multiple contrasts in randomized dose-response trials--confidence interval oriented approaches.
Hothorn LA
J Biopharm Stat; 2006; 16(5):711-31. PubMed ID: 17037267
[TBL] [Abstract][Full Text] [Related]
17. Fallback tests in dose-response clinical trials.
Dmitrienko A; Wiens B; Westfall P
J Biopharm Stat; 2006; 16(5):745-55. PubMed ID: 17037269
[TBL] [Abstract][Full Text] [Related]
18. Assessment of type I error rate associated with dose-group switching in a longitudinal Alzheimer trial.
Habteab Ghebretinsae A; Molenberghs G; Dmitrienko A; Offen W; Sethuraman G
J Biopharm Stat; 2014; 24(3):660-84. PubMed ID: 24697817
[TBL] [Abstract][Full Text] [Related]
19. Designing multiregional trials under the discrete random effects model.
Lan KK; Pinheiro J; Chen F
J Biopharm Stat; 2014; 24(2):415-28. PubMed ID: 24605977
[TBL] [Abstract][Full Text] [Related]
20. Stopping trials early for benefit: too good to be true.
Lancet; 2008 Apr; 371(9621):1310. PubMed ID: 18424306
[No Abstract] [Full Text] [Related]
[Next] [New Search]
